Auf dem Weg zu einer neuen Behandlungsqualität der Neurodermitis

This study analyses the treatment of atopic dermatitis (AD), a common but still incurable disease, in 16 of Germany’s 17 statutory health insurance (KV) regions. Newly developed quality indicators of AD along with measurement parameters for disease severity, quality of life impairment and patient benefit were evaluated, revealing new indications of regional differences in treatment in individual KV regions. Targeted prescription of topical immunomodulators instead of the widely used topical glucocorticosteroids could intensify and improve AD therapy considerably, saving costs in the long term. The recommendation of health policymakers and the Federal Joint Committee on healthcare (G-BA) would be required for this. These findings could improve the existing standard of care for over one million AD patients nationwide. The new measurement parameter could also be applied to other fields of medicine, such as nursing care.